metformin has been researched along with pci 32765 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bates, PD; Bebel, S; Capitini, CM; Chen, M; Chen, R; Daenthanasanmak, A; Gao, X; Hoang, NM; Kenkre, VP; Kimpara, S; Li, Y; Liu, Y; Lu, L; Ngo, VN; Rui, L; Selberg, PE; Song, L; Waldmann, TA; Zhang, X | 1 |
2 other study(ies) available for metformin and pci 32765
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma.
Topics: Adult; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Metformin; Mice; Oxidative Phosphorylation | 2023 |